Evidence map›Paper›PMID 38658543›Full record

ArticleNature communications2024

EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.

Pierre Romero, Laia Richart, Setareh Aflaki, Ambre Petitalot, Megan Burton, Audrey Michaud, Julien Masliah-Planchon, Frédérique Kuhnowski, Samuel Le Cam, Carlos Baliñas-Gavira and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Molecular Insights and Novel Therapies for Lymphoproliferative Disorders.International journal of molecular sciences · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Pierre Romero *Institut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France.ORCID http://orcid.org/0000-0001-8609-1203
Laia Richart *Institut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France.
Setareh AflakiInstitut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France.
Ambre PetitalotInstitut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France.
Megan BurtonInstitut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France.
Audrey MichaudInstitut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France.
Julien Masliah-PlanchonInstitut Curie, Pharmacogenetics Unit, Department of Genetics, Paris Sciences et Lettres Research University, Paris, France.
Frédérique KuhnowskiInstitut Curie, Department of Clinical Hematology, Paris Sciences et Lettres Research University, Paris, France.
Samuel Le CamInstitut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France.ORCID http://orcid.org/0000-0002-7172-6226
Carlos Baliñas-GaviraInstitut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France.ORCID http://orcid.org/0000-0002-7535-5426
Céline MéaudreInstitut Curie, Department of Pathology, Paris Sciences et Lettres Research University, Paris, France.
Armelle LuscanInstitut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France.
Abderaouf HamzaInstitut Curie, Pharmacogenetics Unit, Department of Genetics, Paris Sciences et Lettres Research University, Paris, France.ORCID http://orcid.org/0000-0001-6977-4213
Patricia LegoixInstitut Curie, Genomics of Excellence (ICGex) Platform, Paris Sciences et Lettres Research University, Paris, France.
Anne Vincent-SalomonInstitut Curie, Department of Pathology, Paris Sciences et Lettres Research University, Paris, France.ORCID http://orcid.org/0000-0001-5754-5771
Michel WassefInstitut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France.
Daniel HolochInstitut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France. daniel.holoch@curie.fr.ORCID http://orcid.org/0000-0001-6399-0230
Raphaël MargueronInstitut Curie, INSERM U934/CNRS UMR 3215, Paris Sciences et Lettres Research University, Sorbonne University, Paris, France. raphael.margueron@curie.fr.ORCID http://orcid.org/0000-0002-9093-7977
Centre National de la Recherche Scientifique · FRInstitut Curie · FRUniversité Paris Sciences et Lettres · FR

Funding

Agence Nationale de la Recherche (French National Research Agency) ANR-10-EQPX-03Agence Nationale de la Recherche (French National Research Agency) ANR-10-INBS-09-08Fondation pour la Recherche Médicale (Foundation for Medical Research in France) SPF20150934266
6 · The paper itself

Abstract

Mutations in chromatin regulators are widespread in cancer. Among them, the histone H3 lysine 27 methyltransferase Polycomb Repressive Complex 2 (PRC2) shows distinct alterations according to tumor type. This specificity is poorly understood. Here, we model several PRC2 alterations in one isogenic system to reveal their comparative effects. Focusing then on lymphoma-associated EZH2 mutations, we show that Ezh2

Indexed as

Enhancer of Zeste Homolog 2 ProteinHistonesLymphoma, FollicularMutationPolycomb Repressive Complex 2Cell Line, TumorChromatinGene Expression Regulation, NeoplasticHumansMethylationTranscription, GeneticChromatinEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistonesPolycomb Repressive Complex 2

Identifiers

PMID38658543
PMCPMC11043461
OpenAlexW4395076394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.